The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Pari Malherbe

F. Hoffmann-La Roche Ltd

Discovery Research CNS

CH-4070 Basel

Switzerland +41 61 68 86286 ;


Name/email consistency: high



  • F. Hoffmann-La Roche Ltd, Discovery Research CNS, CH-4070 Basel, Switzerland +41 61 68 86286 ;. 2011
  • Discovery Research CNS, F. Hoffmann-La Roche Ltd., Basel, Switzerland. 2003 - 2011
  • Pharma Division PRPN, Bldg. 69/333, Preclinical CNS Research, F. Hoffmann-La Roche, Switzerland. 1999 - 2006


  1. Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010). Malherbe, P., Ballard, T.M., Ratni, H. Expert. Opin. Ther. Pat (2011) [Pubmed]
  2. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors. Malherbe, P., Knoflach, F., Hernandez, M.C., Hoffmann, T., Schnider, P., Porter, R.H., Wettstein, J.G., Ballard, T.M., Spooren, W., Steward, L. Br. J. Pharmacol. (2011) [Pubmed]
  3. Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Malherbe, P., Roche, O., Marcuz, A., Kratzeisen, C., Wettstein, J.G., Bissantz, C. Mol. Pharmacol. (2010) [Pubmed]
  4. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Malherbe, P., Borroni, E., Gobbi, L., Knust, H., Nettekoven, M., Pinard, E., Roche, O., Rogers-Evans, M., Wettstein, J.G., Moreau, J.L. Br. J. Pharmacol. (2009) [Pubmed]
  5. Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures. Malherbe, P., Kratzeisen, C., Marcuz, A., Zenner, M.T., Nettekoven, M.H., Ratni, H., Wettstein, J.G., Bissantz, C. J. Med. Chem. (2009) [Pubmed]
  6. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists. Malherbe, P., Borroni, E., Pinard, E., Wettstein, J.G., Knoflach, F. Mol. Pharmacol. (2009) [Pubmed]
  7. Characterization of (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABAB receptors. Malherbe, P., Masciadri, R., Norcross, R.D., Knoflach, F., Kratzeisen, C., Zenner, M.T., Kolb, Y., Marcuz, A., Huwyler, J., Nakagawa, T., Porter, R.H., Thomas, A.W., Wettstein, J.G., Sleight, A.J., Spooren, W., Prinssen, E.P. Br. J. Pharmacol. (2008) [Pubmed]
  8. Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Malherbe, P., Bissantz, C., Marcuz, A., Kratzeisen, C., Zenner, M.T., Wettstein, J.G., Ratni, H., Riemer, C., Spooren, W. Mol. Pharmacol. (2008) [Pubmed]
  9. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. Malherbe, P., Kratochwil, N., Mühlemann, A., Zenner, M.T., Fischer, C., Stahl, M., Gerber, P.R., Jaeschke, G., Porter, R.H. J. Neurochem. (2006) [Pubmed]
  10. Opposite effects of Zn on the in vitro binding of [3H]LY354740 to recombinant and native metabotropic glutamate 2 and 3 receptors. Malherbe, P., Richards, J.G., Broger, C., Zenner, M.T., Messer, J., Kratzeisen, C., Nakanishi, S., Mutel, V. J. Neurochem. (2005) [Pubmed]
  11. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. Malherbe, P., Kratochwil, N., Knoflach, F., Zenner, M.T., Kew, J.N., Kratzeisen, C., Maerki, H.P., Adam, G., Mutel, V. J. Biol. Chem. (2003) [Pubmed]
  12. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Malherbe, P., Kratochwil, N., Zenner, M.T., Piussi, J., Diener, C., Kratzeisen, C., Fischer, C., Porter, R.H. Mol. Pharmacol. (2003) [Pubmed]
  13. Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. Malherbe, P., Mutel, V., Broger, C., Perin-Dureau, F., Kemp, J.A., Neyton, J., Paoletti, P., Kew, J.N. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  14. Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. Malherbe, P., Kew, J.N., Richards, J.G., Knoflach, F., Kratzeisen, C., Zenner, M.T., Faull, R.L., Kemp, J.A., Mutel, V. Brain Res. Mol. Brain Res. (2002) [Pubmed]
  15. Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Malherbe, P., Kratzeisen, C., Lundstrom, K., Richards, J.G., Faull, R.L., Mutel, V. Brain Res. Mol. Brain Res. (1999) [Pubmed]
  16. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Malherbe, P., Richards, J.G., Gaillard, H., Thompson, A., Diener, C., Schuler, A., Huber, G. Brain Res. Mol. Brain Res. (1999) [Pubmed]
WikiGenes - Universities